Biophytis SA (BPTSY)
8.99
+1.49
(+19.87%)
USD |
OTCM |
May 07, 16:00
Biophytis Cash from Financing (TTM): 7.617M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.617M |
| June 30, 2023 | 4.480M |
| December 31, 2022 | 6.515M |
| June 30, 2022 | 19.28M |
| December 31, 2021 | 35.10M |
| June 30, 2021 | 41.35M |
| December 31, 2020 | 25.66M |
| Date | Value |
|---|---|
| June 30, 2020 | 28.74M |
| December 31, 2017 | 29.70M |
| June 30, 2017 | 7.899M |
| December 31, 2016 | 0.4241M |
| June 30, 2016 | 11.60M |
| December 31, 2015 | 13.92M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
4.480M
Minimum
Jun 2023
41.35M
Maximum
Jun 2021
21.09M
Average
22.47M
Median
Cash from Financing (TTM) Benchmarks
| Edap TMS SA | -0.9863M |
| DBV Technologies SA | 6.767M |
| Cellectis SA | 82.86M |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | 0.88M |